Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

Table 2

Competitive environment.

Agent	Indication	Development stage	Mechanism of action
Brentuximab vedotin	HL, NHL	Approved for HL and NHL	Anti-CD30 antibody-drug conjugate
Bendamustine	NHL, MM	Approved for NHL	Bifunctional alkylating agent
Panobinostat	AML, CML, breast cancer, prostate cancer, MM, idiopathic myelofibrosis, HL, NHL	Approved for MM	HDAC inhibitor
Mocetinostat	AML, solid tumors, CLL, MDS, NHL, HL	Phase II	HDAC inhibitor
Everolimus	Solid tumors, transplant rejection, HL, NHL	Approved for solid tumors and transplant rejection	mTOR inhibitor
Pacritinib	AML, myeloproliferative disorders, HL, NHL	Phase III	JAK2-inhibitor
Rituximab	NHL, CLL, rheumatoid arthritis, HL, granulomatosis, multiple sclerosis, MM	Approved for NHL, rheumatoid arthritis, granulomatosis, CLL	Anti-CD20 antibody
Lenalidomide	MDS, MM, NHL, HL, CLL	Approved for MDS, MM	Immunomodulator
Nivolumab	Melanoma, lung cancer, renal cancer, HL	Phase I	Anti-PD1 antibody
Pembrolizumab	Melanoma, lung cancer, renal cancer, HL	Phase I	Anti-PD1 antibody

HL: Hodgkin lymphoma; NHL: non-Hodgkin lymphoma; MM: multiple myeloma; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; CLL: chronic lymphatic leukemia.